Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.7 USD | -0.19% | -1.70% | -3.97% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.97% | 184B | |
-1.26% | 107B | |
-3.48% | 69.44B | |
+3.07% | 50.37B | |
+8.46% | 44.82B | |
+3.40% | 41.53B | |
+3.00% | 26.84B | |
+3.97% | 26.73B | |
+15.23% | 25.71B | |
-1.29% | 24.34B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating